Myriad Genetics, Inc. (NASDAQ:MYGN)
| CAPS Rating |
|
|---|
MYGN
VS S&P 500 (SPY)
MYGN News and Commentary
- Cepheid Expands European Portfolio - Analyst Blog – NASDAQ
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 5 – SeekingAlpha
- FDA Nod for Cepheid's Infinity-80 - Analyst Blog – NASDAQ
- 5-Star Stocks Poised to Pop: Myriad Genetics – The Motley Fool
- Myriad in Research Partnership - Analyst Blog – NASDAQ
- Genomic Health Stays Neutral - Analyst Blog – NASDAQ
- Top Analyst Upgrades & Downgrades (AVP, BAC, BBY, BA, DCI, FB, GS, HLF, KIRK, MS, MYGN, NUAN, PBR, R – 247wallst
- Myriad Reiterated Neutral - Analyst Blog – NASDAQ
- An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABP – 247wallst
How do you think MYGN will perform against the market?
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPSAll Players
519
Outperform
79
Underperform
All-Star Players
143
Outperform
9
Underperform
Wall Street
18
Outperform
2
Underperform
RSS Headlines
Fool UK
